Antiemetics

Choose the drug in a safety-first sequence

A good antiemetic decision identifies the circuit before it stacks adverse effects.

First separate vestibular motion, gastrointestinal stasis, toxin or chemotherapy exposure, and postoperative risk because each context weights the receptors differently.

Then decide whether treatment is rescue or prophylaxis and whether a combination is needed; highly emetogenic chemotherapy usually requires complementary mechanisms rather than serial monotherapy.

Before prescribing, review the ECG and electrolytes, serotonergic drugs, Parkinson disease or prior EPS, bowel motility, glaucoma or urinary retention, sedation risk, pregnancy considerations, and interaction-prone medicines.

The vomiting network spans gut, brainstem, and vestibular system

Receptor geography explains why a drug can excel in one context and fail in another.

Enterochromaffin-cell serotonin activates vagal 5-HT3 afferents after mucosal injury or chemotherapy, carrying a peripheral signal toward the nucleus tractus solitarius.

The area postrema lies outside the usual blood-brain barrier and samples circulating emetogens through dopamine, serotonin, NK1, and other receptors.

Vestibular nuclei send histamine H1 and muscarinic M1 input during motion mismatch, so centrally penetrating antihistamines and scopolamine outperform a purely gut-focused strategy.

The adverse effect reveals the receptor

A new motor, endocrine, cardiac, or cognitive finding often identifies the antiemetic class.

D2 blockade in the nigrostriatal pathway produces acute dystonia, akathisia, parkinsonism, and tardive dyskinesia, while tuberoinfundibular blockade raises prolactin.

5-HT3 antagonists can prolong QT, especially when congenital long QT, bradyarrhythmia, heart failure, low potassium or magnesium, or other QT-prolonging drugs are present.

H1 and M1 drugs commonly sedate and impair cognition; antimuscarinic effects add dry mouth, blurred vision, constipation, urinary retention, and angle-closure glaucoma risk.

D2 blockade can move the limbs and the prolactin level at the same time.

Six receptor strategies, six different jobs

Antiemetics are not interchangeable because the dominant input changes with the cause of emesis.

5-HT3 antagonists block serotonin signaling at gastrointestinal vagal afferents and central emetic pathways, making them useful for chemotherapy-related and postoperative nausea, but they do not solve every vestibular or motility problem.

D2 antagonists suppress area postrema signaling; metoclopramide also promotes upper gastrointestinal motility, which can help diabetic gastroparesis but does not remove its central dopamine adverse effects.

NK1 antagonists block substance P and are especially useful as part of combination prophylaxis for highly emetogenic chemotherapy and selected postoperative settings.

First-generation H1 antihistamines and M1 antimuscarinics reach central vestibular pathways, which explains both their value in motion sickness and their sedation, dry mouth, blurred vision, and cognitive effects.

Selected cannabinoid agonists such as dronabinol or nabilone can be considered for chemotherapy-related nausea that persists despite standard therapy, but psychoactive, hemodynamic, and sedating effects limit routine use.

Start with the source of the emetic signal, not the drug name you remember fastest.

Time turns several warnings into testable decisions

The relevant numbers are treatment windows, not a promise that a larger dose fixes the wrong pathway.

Delayed chemotherapy-related emesis becomes prominent after the first 24 hours, which is why NK1 coverage matters beyond the acute 5-HT3-dominant phase.

After aprepitant begins, a patient on chronic warfarin needs INR attention during the next 2 weeks, especially around days 7 to 10, and hormonal contraceptive backup continues for 28 days after the last dose.

For diabetic gastroparesis, the 2026 Reglan label says to avoid total metoclopramide treatment longer than 12 weeks unless longer use is unavoidable and motor symptoms are routinely monitored.

When the clock changes, the dominant risk or pathway can change with it.

The interaction list is part of the mechanism

A receptor match is incomplete until additive toxicity and metabolism have been checked.

Ondansetron deserves extra caution with congenital long QT, electrolyte depletion, bradyarrhythmia, heart failure, or other QT-prolonging drugs; concomitant serotonergic therapy also raises a labeled serotonin-syndrome warning.

Metoclopramide should be used for the shortest appropriate duration, avoided with prior tardive dyskinesia, and reconsidered when antipsychotics or other dopamine blockers increase motor toxicity.

Aprepitant is a CYP3A4 substrate and inhibitor-inducer with clinically important effects on interacting drugs; it can decrease warfarin INR and reduce hormonal contraceptive efficacy.

H1, M1, and cannabinoid strategies can add to alcohol, opioid, benzodiazepine, and other sedative effects, so driving, falls, delirium, and respiratory vulnerability matter.